Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GSTO1 | P78417 | 2/20 | 0.45 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | MRE11 | P49959 | 1/20 | 0.41 |
| ▸ | ATP4A | P20648 | 2/20 | 0.40 |
| ▸ | ATP4B | P51164 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225993 | 0.85 | RAB9A (0.50) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL13118019 | 0.83 | LTA4H (0.54) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2228103 | 0.82 | RAB9A (0.49) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2228668 | 0.82 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL2225700 | 0.77 | LTA4H (0.55) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2406442 | 0.77 | POLB (0.59) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL2226326 | 0.77 | MAPT (0.36) | L3MBTL1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL2225749 | 0.72 | L3MBTL1 (0.53) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL15160564 | 0.72 | KDM4E (0.71) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 | |
| SCHEMBL25140728 | 0.72 | LTA4H (0.58) | LTA4HL3MBTL1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2533783-B1 | COMPOUNDS AND METHODS for the inhibition of HDAC | TEMPERO PHARMACEUTICALS INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| CN-103221047-B | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2014-12-17 | — | — | CN | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| CN-103221047-A | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2013-07-24 | — | — | CN | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059883-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2013-03-07 | — | — | US | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | LTA4H 814/4885L3MBTL1 499/4885ALDH1A1 1152/4885 |
| US-20130059883-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | LTA4H 814/4885L3MBTL1 499/4885ALDH1A1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.